Momenta Pharmaceuticals, Inc. (MNTA)

[io_io]

Estimated NPV of MNTA's Lovenox royalty stream: #msg-87412567.

Dew, well its collapsed from $3 per this post to $2 now, all within the space of months.

But even so, is your new NPV valid?

After all, here is today's conf call:

Craig A. Wheeler - President, Chief Executive Officer and Director
Sandoz reported first quarter enoxaparin net sales of $47 million, a significant decrease from Sandoz’s fourth quarter 2012 enoxaparin net sales of $85 million. The decrease primarily reflects the continued impact of competitive pricing and lower unit sales. Rick will provide additional context in his remarks, but clearly the enoxaparin market remains competitive.

And then in the Q+A:

Eric Schmidt - Cowen & Co.
If you could just give it for a moment to the Lovenox parent franchise and a pretty significant quarter-on-quarter decline, it sounds like Rick that is mostly pricing is that right, was there any, I don’t know one-time items shipping changes, inventory distribution issues that worth noted in that decline?

Richard P. Shea - Chief Financial Officer and Senior Vice President
Eric it was about half volume and half pricing as far as the change from Q4 to Q1. So, existing customers just took less products in the first quarter than they did in the fourth quarter.